- Home
- SLRX vs PRFX Comparison
SLRX vs PRFX Comparison
Compare SLRX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- PRFX
- Stock Information
- Founded
- SLRX N/A
- PRFX 2007
- Country
- SLRX United States
- PRFX Israel
- Employees
- SLRX N/A
- PRFX N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- PRFX Health Care
- Exchange
- SLRX Nasdaq
- PRFX Nasdaq
- Market Cap
- SLRX 2.9M
- PRFX 3.3M
- IPO Year
- SLRX N/A
- PRFX 2020
- Fundamental
- Price
- SLRX $4.65
- PRFX $1.39
- Analyst Decision
- SLRX
- PRFX Hold
- Analyst Count
- SLRX 0
- PRFX 1
- Target Price
- SLRX N/A
- PRFX N/A
- AVG Volume (30 Days)
- SLRX 124.5K
- PRFX 8.7M
- Earning Date
- SLRX 08-12-2025
- PRFX 09-19-2025
- Dividend Yield
- SLRX N/A
- PRFX N/A
- EPS Growth
- SLRX N/A
- PRFX N/A
- EPS
- SLRX N/A
- PRFX N/A
- Revenue
- SLRX N/A
- PRFX N/A
- Revenue This Year
- SLRX N/A
- PRFX N/A
- Revenue Next Year
- SLRX N/A
- PRFX N/A
- P/E Ratio
- SLRX N/A
- PRFX N/A
- Revenue Growth
- SLRX N/A
- PRFX N/A
- 52 Week Low
- SLRX $4.61
- PRFX $1.25
- 52 Week High
- SLRX $108.00
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- SLRX 31.39
- PRFX 45.79
- Support Level
- SLRX $4.61
- PRFX $1.34
- Resistance Level
- SLRX $6.28
- PRFX $1.80
- Average True Range (ATR)
- SLRX 0.54
- PRFX 0.28
- MACD
- SLRX 0.05
- PRFX -0.02
- Stochastic Oscillator
- SLRX 1.92
- PRFX 2.22
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.